How can minimal residual disease be used to predict response to treatment for myeloid malignancies?

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

Learn more on this topic: New Directions in Myeloid Malignancies

Related Material

What are the best ways to monitor minimal residual disease in myeloid malignancies?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.